Home Therapeutic relationship AREV Life Sciences advances developments, new appointments

AREV Life Sciences advances developments, new appointments


VANCOUVER, British Columbia, Feb. 17, 2022 (GLOBE NEWSWIRE) — via InvestorWire — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) today announces its new business acquisitions and the maturation of several product lines which are associated with appointments and the expansion of the company’s capacity within the Scientific Advisory Board and Intellectual Property Board of the Company.

The Company is pleased to announce the appointment of Douglas Sorocco to its Scientific Advisory Board and Intellectual Property Council, as well as the expansion of the Company’s services with Strategic Health Resources LLC. AREV’s growing portfolio of consumer products and therapeutic innovations is now entering mature development phases.

Given the global impact of this contemporary global famine and the appearance of Elon Musk being challenged to respond to requests for support from the World Food Program, AREV Life Sciences is expanding its efforts to ensure that SUSTAINN, its ready-to-use therapeutic food for use currently in development, can meet the challenges of securing SUSTAINN’s inclusion in the global formulary.

“I am very pleased to have Doug Sorocco be part of this critical effort that is positioned to both drive company profitability and relief for patient populations in need of viable approaches to treat starvation,” Roscoe said. Moore, DVM, MPH, Ph.D.; former Assistant United States Surgeon General (retired); Board Member, Global Virus Network; Institute of Human Virology University of Maryland School of Medicine; and who chairs AREV’s scientific advisory committee.

Doug Sorocco, Esq., will act as the Company’s patent attorney and intellectual property advisor for its maturing intellectual property portfolio. He practices in all areas of intellectual property law, including patents, trademarks, copyright and technology, and assists clients with intellectual property matters requiring litigation, licensing, technology advice and complex transactions.

Sorocco is licensed to practice before the United States Patent and Trademark Office. His practice has focused on the acquisition and/or commercialization of intellectual property assets as well as portfolio management, licensing and transactional matters. Sorocco is ranked in group 1 (the best group) for intellectual property law by the highly reputable “Chambers USA: Americas Leading Lawyers for Business 2021”, and he was selected to be listed in “The Best Lawyers in America® 2022” for litigation – intellectual property, litigation – patents, patent law and technology law. In 2021, Best Lawyers named him Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to classify Sorocco as an IP Star.

Sorocco’s scientific training has focused on all areas of biotechnology and life sciences (including molecular biology, cell biology, glycobiology, biochemistry, developmental biology, immunology, microbiology , virology and genetics; pharmaceutical compositions; molecular diagnostics and techniques; and medical devices and equipment) as well as chemistry and chemical engineering. He has extensive experience in providing strategic and tactical intellectual property advice to individual clients, universities, large pharmaceutical and manufacturing companies, and start-up biotechnology companies. He is currently an adjunct faculty member at Oklahoma City University School of Law and served as an adjunct in the Department of Physiology at the University of Oklahoma Health Sciences Center. Prior to joining Dunlap Codding in 1996, Sorocco worked for Dick & Harris, an intellectual property law firm in Chicago. He was named one of the 15 Minority Rainmakers of the Year in 2014 by the Minority Corporate Counsel Association. In 2016, he received the George Lewis Advocacy Award from the Oklahoma City Mayor’s Committee on Disability Issues.

These new additions to AREVThe company’s efforts ensure the acceleration of the company’s immediate goals as we move closer to market entry with flagship products,” said Mike Withrow, CEO of AREV Life Sciences. Our corporate leadership is fully committed to keeping pace with the capabilities of senior management and our advisory boards as we advance product development and research efforts in our human nutrition and preclinical phytomedical therapeutic research with a array of emerging business partners to deliver value. to investors and create paradigm shifts in the treatment of starvation and to address other clinical disparities faced by patient populations and the broader consumer market.

AREV is expanding its relationship with Strategic Health Resources LLC (SHR), a healthcare-focused government relations consulting firm based in Arlington, Virginia. With over 30 years of in-depth experience advancing legislation for the healthcare industry and small cap biotech sector, SHR is responsible for addressing committees that have jurisdiction to facilitate inclusion of SUSTAINN in the USAID approved list of RUTFs. The UNICEF-WHO-WB Interagency Group on Joint Child Malnutrition Estimates regularly updates global and regional prevalence estimates and figures for each indicator. In 2020, globally, 149.2 million children under 5 were stunted, 45.4 million were wasted and 38.9 million were overweight. Currently, 61 countries have some form of treatment for severe acute malnutrition. Most ready-to-use therapeutic foods (RUTF) are used in emergency response. UNICEF provides approximately 75-80% of the global RUTF demand, averaging 49,000 metric tons (MT) per year over the past four years, suitable for treating 3.5 million children.1 Despite high volumes through UNICEF, this still only covers 25% of the estimated number of children worldwide suffering from severe wasting. RUTFs purchased by governments, non-governmental organizations (NGOs) and other United Nations (UN) agencies cover an additional 5-10%. Thus, approximately 65-70% of children suffering from severe wasting worldwide do not have access to treatment.

In addition, the Company is pleased to announce that it has issued 100,000 stock options to directors, officers and consultants of the Company at a price of $0.29 for a period of five years from date of issue. These options will vest immediately.

For more information, contact Mike Withrow, [email protected], 778-929-6536. For more information, visit www.arevlifesciences.com.

On behalf of the Board of Directors,
mike withrow
CEO and Director

ABOUT AREV Life Sciences Global Corp.

AREV Life Sciences Global Corp. is a fully integrated, publicly traded, early-stage life sciences company dedicated to delivering therapeutic public health interventions through unique compound extraction, discovery, innovation and successful collaborations. The company’s leadership drives discovery programs for the clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV invests in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for the associated chronic neglected comorbidities and innovations in human nutrition. AREV is dedicated to designing and delivering innovations in rational drug design, driven by presenting the global epidemiological characteristics of the multiple challenges in international human and animal health. AREV is a member of BIOTECanada and the Biotechnology Innovation Organization (BIO).


Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements contained herein, other than statements of historical fact, should be considered forward-looking. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include market prices; mining and exploration success; the continued availability of capital and financing; and general economic, market or business conditions. There can be no assurance that such statements will prove to be accurate and, therefore, readers are urged to rely on their own assessments of these uncertainties. We undertake no obligation to update forward-looking statements, except as required by applicable law. This press release contains forward-looking statements. Use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “shall”, “project”, “should”, “believe” and the like similar expressions is intended to identify -looking statements. Although the Company believes that the expectations and assumptions on which forward-looking statements are based are reasonable, undue reliance should not be placed on forward-looking statements as the Company cannot guarantee that they will prove to be accurate. Because forward-looking statements address future events and conditions, they, by their very nature, involve inherent risks and uncertainties.

These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks discussed in the Company’s MD&A under the Company’s profile on www.sedar.com.

Contact wire service
InvestorWire (IW)
Los Angeles, California
212.418.1217 Office
[email protected]